Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 29, 2025
Finance
Autoimmune play Hillstar takes wing with $67M series A: Finance Report
Plus: Novo Holdings, Jeito lead week’s largest A round for VIB company Augustine — and more
BioCentury | Feb 15, 2025
Management Tracks
Robert Michael to succeed Gonzalez as Abbvie’s chair
Plus: Olazábal leaving Ysios and updates from Augustine and Prolific
BioCentury | Nov 27, 2024
Discovery & Translation
Science Spotlight: Reducing immune rejection of stem cell-derived therapies
BioCentury’s roundup of translational innovation also includes a new target for arrhythmia and four papers with links to newcos
BioCentury | Jun 28, 2024
Finance
Venture Report: Curie.Bio’s fund; megarounds for Formation, EvolutionaryScale, BillionToOne
Plus: New fundings for Exsilio, TwoStep and Augustine
BioCentury | Nov 8, 2023
Data Byte
Chong Kun Dang-Novartis deal biggest for Korea in five years
Two South Korean biotechs receive large upfront fees in pharma deals this week
BioCentury | Sep 12, 2023
Emerging Company Profile
Actio seeks rare toeholds into common diseases with $55M A round
Led by geneticist David Goldstein, the San Diego company thinks its ‘one-to-many’ strategy builds the economic case for going after very rare diseases
BioCentury | Nov 12, 2022
Regulation
Nov. 11 Quick Takes: FDA approves Imfinzi for metastatic NSCLC
Plus: Livtencity expands its territory to European markets, and updates from Apexigen, Biosplice and Avstera
BioCentury | Jul 8, 2022
Discovery & Translation
Ring’s immune-evading anelloviruses; plus Tenaya, Goldfinch and Coagulant
BioCentury’s roundup of translational news
BioCentury | Jul 5, 2022
Distillery Therapeutics
Blocking HDAC6-ubiquitin interactions for Zika and influenza
Items per page:
1 - 10 of 84